NasdaqGS:NBIXBiotechs
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income
Neurocrine Biosciences (NBIX) is drawing attention after recent trading left the shares about 13% lower over the past 3 months and roughly 9% lower year to date, despite positive annual revenue and net income growth.
See our latest analysis for Neurocrine Biosciences.
At a latest share price of $127.68, the stock’s short term share price momentum has been soft, yet the 1 year total shareholder return of 14.08% and 3 year total shareholder return of 31.56% indicate a stronger longer term...